Advertisement
U.S. markets open in 2 hours 19 minutes
  • S&P Futures

    5,305.75
    -2.50 (-0.05%)
     
  • Dow Futures

    40,138.00
    -6.00 (-0.01%)
     
  • Nasdaq Futures

    18,492.75
    -11.00 (-0.06%)
     
  • Russell 2000 Futures

    2,136.50
    -1.90 (-0.09%)
     
  • Crude Oil

    82.24
    +0.89 (+1.09%)
     
  • Gold

    2,231.70
    +19.00 (+0.86%)
     
  • Silver

    24.78
    +0.03 (+0.13%)
     
  • EUR/USD

    1.0793
    -0.0036 (-0.33%)
     
  • 10-Yr Bond

    4.1960
    0.0000 (0.00%)
     
  • Vix

    12.99
    +0.21 (+1.64%)
     
  • dólar/libra

    1.2619
    -0.0019 (-0.15%)
     
  • USD/JPY

    151.3720
    +0.1260 (+0.08%)
     
  • Bitcoin USD

    70,834.90
    +744.45 (+1.06%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,953.66
    +21.68 (+0.27%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

Today's Research Reports on Stocks to Watch: Century Aluminum and Inovio Pharmaceuticals

NEW YORK, NY / ACCESSWIRE / June 9, 2017 / U.S. markets were relatively quiet Thursday as former FBI Director James Comey's testimony in front of the U.S. Senate Intelligence Committee did not provide any significant revelations that could impact Donald Trump's presidency. The Dow Jones Industrial Average gained 0.04 percent to close at 21,182.53, while the S&P 500 Index gained 0.03 percent to close at 2,433.79.

"Testimony would have to be really, really damning enough to throw all of [Trump's policy promises] into the trash bin, and that's not what we have right now in this [Comey] testimony," said Mike Antonelli, Chief Equity Sales Trader at Robert W. Baird & Co.

RDI Initiates Coverage on:

Century Aluminum Co.
https://ub.rdinvesting.com/news/?ticker=CENX

Inovio Pharmaceuticals Inc.
https://ub.rdinvesting.com/news/?ticker=INO

Century Aluminum's shares spiked 14.27 percent to close at $16.90 a share on Thursday. The stock traded between $14.72 and $16.97 on volume of 4.93 million shares traded. President and Chief Executive Officer Mike Bless recently spoke at the Deutsche Bank 8th Annual Global Industrials & Materials Summit Conference in Chicago on June 8th. The company reported revenues were $365.8 million for the first quarter of 2017, an increase of 8 percent increase when compared to the fourth quarter of 2016. Net loss was $15.1 million, or $0.17 per share, for the first quarter of 2017. Shares of Century Aluminum have gained approximately 97.43 percent year-to-date.

Access RDI's Century Aluminum Research Report at:
https://ub.rdinvesting.com/news/?ticker=CENX

Inovio Pharmaceuticals' shares jumped 10.83 percent to close at $8.19 a share on Thursday. The stock traded between $7.47 and $8.33 on volume of 5.07 million shares traded. On June 8th, the company announced that it has begun a phase 3 clinical trial of Inovio's DNA-based immunotherapy, VGX-3100, for the treatment of cervical dysplasia caused by human papillomavirus (HPV). The FDA had previously placed a clinical hold on the program as it requested more information relating to the CELLECTRA 5PSP delivery device. Shares of Inovio Pharmaceuticals have gained approximately 18.01 percent year-to-date.

Dr. Mark Bagarazzi, Inovio's Chief Medical Officer, said, "Despite the availability of preventive HPV vaccines for over a decade, HPV-related cervical HSIL and cancers remain a widely prevalent problem. Unfortunately, current treatments are invasive and do not address the underlying HPV infection."

Access RDI's Inovio Pharmaceuticals Research Report at:
https://ub.rdinvesting.com/news/?ticker=INO

Our Actionable Research on Century Aluminum Co. (NASDAQ: CENX) and Inovio Pharmaceuticals Inc. (NASDAQ: INO) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Hemal K. Gandhi, CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com


Advertisement